BridgeBio Pharma, Inc. (BBIO) News
Track canonical SquawkNews coverage tagged to BBIO, BridgeBio Pharma, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 45 indexed stories across 23 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BridgeBio Pharma, Inc. (BBIO) RWE: Acoramidis Cuts Clinical Worsening Risk 34% vs Tafamidis
BridgeBio reported peer-reviewed real-world data showing acoramidis was associated with a 34% lower risk of a composite of clinical worsening events vs tafamidis in ATTR-CM (p=0.046), with a 43% lower risk of diuretic in
NEWS | Sep 23, 2026, 11:52 AM UTC
L
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% re
NEWS | Sep 23, 2026, 11:52 AM UTC
L
BBIO - Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
BBIO - Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
NEWS | Sep 23, 2026, 11:47 AM UTC
L
BBIO - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBIO - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 18, 2026, 08:01 PM UTC
L
BBIO: Attruby's clinical edge and new launches drive growth, targeting profitability by 2027
China-originated innovation and AI are shaping operational strategies, while regulatory and pricing dynamics remain key. Attruby is driving growth with strong first-line positioning and clinical differentiation, and new
GEOPOLITICS | Sep 15, 2026, 03:47 PM UTC
L
BBIO: Attruby's clinical edge and pipeline launches drive growth, with break-even targeted by 2027
The conference highlighted strong first-line growth and clinical differentiation for Attruby, robust pipeline progress with infigratinib and BBP-418, and a solid financial position targeting break-even by 2027. AI and Ch
GEOPOLITICS | Sep 15, 2026, 03:09 PM UTC
L
Leerink maintains Outperform on BridgeBio Oncology Thera, cuts PT to $27
Leerink Partners maintained BridgeBio Oncology Thera at Outperform and cut its price target to $27.00 per share from $39.00, according to a ratings-action report.
EQUITY | Sep 10, 2026, 03:18 PM UTC
L
BBIO: Late-stage pipeline advances, with differentiated launches and global expansion underway
Multiple late-stage assets are nearing launch, with Attruby leading in ATTR-CM and strong differentiation supported by clinical and real-world data. BBP-418 and infigratinib show robust efficacy and market potential, whi
EQUITY | Sep 10, 2026, 02:50 PM UTC
L
BBIO: Late-stage pipeline advances with differentiated launches in ATTR-CM, neuromuscular, and skeletal diseases
Multiple late-stage assets are nearing launch, with Attruby leading in ATTR-CM and strong differentiation supported by clinical and real-world data. BBP-418 and infigratinib are positioned for global launches, while enca
EQUITY | Sep 10, 2026, 02:10 PM UTC
L
BridgeBio Pharma price target maintained at $120 by HC Wainwright
EQUITY | Sep 10, 2026, 12:11 PM UTC
L
BBIO: Strong growth and pipeline launches position the business for sustained expansion and innovation
The business is experiencing strong growth with Attruby and anticipates further acceleration from three major drug launches in 2027. Differentiation in ATTR-CM, robust pipeline data, and targeted launch strategies for ra
EQUITY | Sep 09, 2026, 07:30 PM UTC
L
BBIO: Strong growth outlook with multiple late-stage launches and expanding pipeline through 2027
The business is growing strongly, led by acoramidis and a late-stage pipeline with three major launches by 2027. ATTR-CM stabilizers are frontline, with Attruby set for greater market share. Launches in limb-girdle muscu
EQUITY | Sep 09, 2026, 06:31 PM UTC
L
Raymond James cuts BridgeBio Oncology Thera price target to $22
Raymond James maintained a rating of Outperform on BridgeBio Oncology Thera and cut its price target to $22.00 from $24.00, according to Benzinga (TradingView News).
EQUITY | Sep 09, 2026, 06:00 PM UTC
M
BridgeBio late-stage genetic disease therapies set for US launches by 2027
BridgeBio says BBP-418, encaleret, and infigratinib are set for US launches by 2027, supporting a pipeline that includes three approved medicines and late-stage candidates targeting rare genetic diseases.
EQUITY | Sep 09, 2026, 04:45 PM UTC
M
Oral infigratinib in PROPEL 3 shows favorable 52-week trends in children
In PROPEL 3, oral infigratinib treatment for 52 weeks showed favorable trends versus placebo on clinically meaningful exploratory endpoints, including sleep apnea and otitis media events.
EQUITY | Sep 09, 2026, 08:07 AM UTC
M
BBIO oral infigratinib shows benefits in PROPEL 3 phase 3
TradeXchange says BBIO’s oral infigratinib showed meaningful benefits within 52 weeks in children with achondroplasia in the Phase 3 PROPEL 3 trial.
EQUITY | Sep 09, 2026, 08:00 AM UTC
L
HC Wainwright maintains BridgeBio Pharma $120 price target
HC Wainwright & Co. maintained a $120.00/share price target for BridgeBio Pharma.
EQUITY | Sep 02, 2026, 11:38 AM UTC
L
BridgeBio to present late-breaking infigratinib data at ESPE 2026
BridgeBio Pharma said it will present one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia at the Annual ESPE Meeting 2026.
EQUITY | Sep 02, 2026, 11:37 AM UTC
L
BridgeBio to present infigratinib data at ESPE 2026
BridgeBio (BBIO) plans to present new data on oral infigratinib’s impact on medical complications in achondroplasia at the Annual ESPE Meeting 2026.
EQUITY | Sep 02, 2026, 11:30 AM UTC
L
BridgeBio Pharma maintained as Outperform by Mizuho
Mizuho maintained its Outperform rating on BridgeBio Pharma.
EQUITY | Sep 01, 2026, 03:31 PM UTC
L
BridgeBio management to participate in September investor conferences
BridgeBio Pharma, Inc. said members of its management team will participate in September investor conferences.
EQUITY | Sep 01, 2026, 11:37 AM UTC
L
BBIO - BridgeBio to Participate in September Investor Conferences
BBIO - BridgeBio to Participate in September Investor Conferences
EQUITY | Sep 01, 2026, 11:30 AM UTC
L
Trump Administration Reaches Most-Favored-Nation Drug Pricing Deals With 9 Companies
Trump Administration Reaches Most-Favored-Nation Drug Pricing Deals With 9 Companies
GEOPOLITICS | Aug 31, 2026, 08:45 PM UTC
L
BridgeBio announces agreement with U.S. government to improve medicine access
BridgeBio said it has reached an agreement with the U.S. government aimed at improving affordability and access to critical medicines.
EQUITY | Aug 31, 2026, 07:49 PM UTC
L
BBIO announces agreement with U.S. government on medicine affordability
BridgeBio (BBIO) announced an agreement with the U.S. government aimed at improving affordability and access to critical medicines for Americans.
EQUITY | Aug 31, 2026, 07:44 PM UTC
L
Acoramidis claims reversal in ATTR-CM progression and function
TradingView News reports Acoramidis demonstrated reversal of cardiac structural progression and functional decline in ATTR-CM, plus more days alive and free from hospitalization.
EQUITY | Aug 30, 2026, 02:07 PM UTC
M
BBIO Acoramidis claims reversal in ATTR-CM progression and function
BBIO says Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline in ATTR-CM, and increases days alive and free from hospitalization.
EQUITY | Aug 30, 2026, 02:00 PM UTC
L
BridgeBio doses first participant in ASCEND-ATTR Phase 3b/4 study
BridgeBio said the first participant was dosed in its Phase 3b/4 ASCEND-ATTR study evaluating acoramidis on disease regression in ATTR-CM.
EQUITY | Aug 26, 2026, 11:37 AM UTC
L
BridgeBio announces first participant dosed in ASCEND-ATTR
BridgeBio said the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating the long-term effects of acoramidis on disease regression in ATTR-CM.
EQUITY | Aug 26, 2026, 11:30 AM UTC
L
BridgeBio to present acoramidis ATTR-CM extension data at ESC Congress 2026
BridgeBio says it will present new acoramidis data from open-label extension analyses in ATTR-CM at ESC Congress 2026.
GEOPOLITICS | Aug 24, 2026, 11:30 AM UTC
H
BBIO stockholder KKR sells 5M shares in $390M deal
BBIO stockholder KKR sells 5M shares in a $390M offering priced at $78/share, according to the feed.
EQUITY | Aug 14, 2026, 12:02 PM UTC
M
BridgeBio Pharma prices oversubscribed secondary share offering
BridgeBio Pharma (BBIO) announces pricing of an oversubscribed secondary offering aimed at diversifying its institutional shareholder base.
EQUITY | Aug 14, 2026, 11:30 AM UTC
M
BridgeBio Pharma launches secondary common stock offering by existing shareholder
BridgeBio Pharma (BBIO) announces the launch of a secondary offering of common stock on behalf of an existing shareholder; no offering size, pricing, or terms were provided in the alert.
EQUITY | Aug 13, 2026, 09:42 PM UTC
L
BBIO Reports Inducement Grants
BBIO reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Aug 11, 2026, 08:01 PM UTC
H
Earnings Volatility Watch: Applied Materials and 10 Other Stocks Could See Double-Digit Moves This Week
It is a make-or-break week for the AI trade. After the market shrugged off strong results from Advanced Micro Devices Inc. (NASDAQ: AMD ), SanDisk Corp. (NASDAQ: SNDK ) and Western Digital Corp. (NASDAQ: WDC ) last week,
EARNINGS | Aug 09, 2026, 12:01 PM UTC
L
BBIO - BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
BBIO - BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
EARNINGS | Aug 03, 2026, 11:30 AM UTC
L
BBIO -BridgeBio Pharma Files Prospectus Related To Offer And Sale Of Up To 24.6M Common Shares By Selling Stockholders
BBIO -BridgeBio Pharma Files Prospectus Related To Offer And Sale Of Up To 24.6M Common Shares By Selling Stockholders
EQUITY | Jul 24, 2026, 09:30 PM UTC
L
BBIO Bridgebio announces FDA Acceptance of NDA for encaleret for adh1 Bridgebio Pharma - FDA sets pdufa target action date of may 8, 2027 fo
BBIO Bridgebio announces FDA Acceptance of NDA for encaleret for adh1 Bridgebio Pharma - FDA sets pdufa target action date of may 8, 2027 for encaleret NDA
REGULATION | Jul 22, 2026, 11:30 AM UTC
H
Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Shares of Ultra Clean Holdings Inc (NASDAQ: UCTT ) rose sharply in pre-market trading after the company announced the appointment of Michael Keogh as CFO. The company appoints Michael Keogh as CFO, effective Aug. 25, suc
EARNINGS | Jul 09, 2026, 08:53 AM UTC
L
BridgeBio Announces Publication Of New Analyses In Circulation: Heart Failure, Examining Kidney Function In Individuals With Transthyretin A
Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05), with no kidne
EQUITY | Jul 02, 2026, 11:32 AM UTC
L
BridgeBio Pharma Agrees To Sell Up To $1B Of Convertible Preferred Stock To Sixth Street And KKR's HealthCare Royalty
BridgeBio Pharma, Inc. (NASDAQ: BBIO ) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it has enter
EQUITY | Jul 01, 2026, 11:34 AM UTC
H
Reported Sunday, BridgeBio PROPEL 3 Phase 3 Trial Published In NEJM, Oral Infigratinib Demonstrates Statistically Significant Improvements I
Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement v
REGULATION | Jun 29, 2026, 06:31 AM UTC
M
BBIO: Oppenheimer Initiates
Oppenheimer assumes BridgeBio Oncology at Outperform with a price target of $22
EQUITY | Jun 22, 2026, 05:35 PM UTC
M
BBIO Presents Achondroplasia Data
BridgeBio Pharma presents additional data from its Phase 3 pivotal study of oral infigratinib in children with achondroplasia
EQUITY | Jun 22, 2026, 11:35 AM UTC
M
BBIO Presents Trial Results
BridgeBio presents primary results from Phase 3 PROPEL 3 trial of oral infigratinib for children with achondroplasia
EARNINGS | Jun 22, 2026, 11:30 AM UTC